Stay updated with breaking news from Pediatric Study Plan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: ABIVAX / Key word: Annual Results Abivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CEST The issuer is solely responsible for the... | April 19, 2023
Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to planAbivax reports promising Phase 2b maintenance results
19.04.2023 - EQS-News: ABIVAX / Key word(s): Annual Results Abivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax reports 2022 financial results and ...
EQS-News: ABIVAX / Key word(s): Annual ResultsAbivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax reports 2022 financial results and operations update Obefazimod global pivotal phase 3 program (ABTECT...
EQS-News: ABIVAX / Key word(s): StudyAbivax receives FDA agreement on pediatric development plan with obefazimod in IBD 20.12.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax receives FDA agreement on pediatric development plan with obefazimod in IBDThe FDA agreed on...